Publications
Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam HM, Hsieh AC, Faltas BM, Haffner MC, Lee JK. (2024). Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations. Nature Genetics doi: 10.1038/s41588-024-01674-1
Chatterjee SS, Linares JF, Cid-Diaz T, Duran A, Khan MIK, Osrodek M, Brady NJ, Reina-Campos M, Marzio A, Venkadaksrishnan VB, Bakht MK, Khani F, Mosquera JM, Robinson BD, Moyer J, Elemento O, Hsieh AC, Goodrich DW, Rickman DS, Beltran H, Moscat J, Diaz-Meco MT. (2024). Increased translation driven by a non-canonical EZH2 cistrome creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nature Communications doi: 10.1038/s41467-024-53874-2
Koehne EL, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley JE, Yu EY, Hsieh AC, Lee JK, Montgomery RB, Psutka SP, Gore JL, Wright JL. (2024). Adjuvant chemotherapy and survival outcomes after radical cystectomy in variant histology bladder cancer. Clinical Genitourinary Cancer doi: 10.1016/j.clgc.2024.102100
Ghali F, Holt SR, Koehne E, Chen JJ, Weg ES, Liao JJ, Zeng J, Grivas P, Hawley J, Hsieh AC, Montgomery RB, Wright JL. (2024). Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients older than 65. Frontiers in Oncology doi: 10.3389/fonc.2024.1341655
Bakaloudi DR, Koehne EL, Diamantopoulos LN, Holt SK, Sekar RR, Ghali F, Vakar-Lopez F, Nyame YA, Psutka SP, Gore JL, de la Calle C, Lin DW, Schade GR, Liao J, Hsieh AC, Yezefski T, Hawley JE, Yu EY, Montgomery RB, Grivas P, Wright JL. (2024). Small cell bladder cancer: treatment patterns for local disease and associated outcomes. A retrospective cohort study. Clinical Genitourinary Cancer doi: 10.1016/j.clgc.2024.102208
Jana S, Brahma S, Arora S, Wladyka CL, Hoang P, Blinka S, Hough R, Horn JL, Liu Y, Wang L, Depeille P, Smith E, Montgomery RB, Lee JK, Haffner MC, Vakar-Lopez F, Grivas P, Wright JL, Lam HM, Black PC, Roose JP, Ryazanov AG, Subramaniam AR, Henikoff S, Hsieh AC. (2023). Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression. Cancer Cell doi: 10.1016/j.ccell.2023.03.021
Schuster SL, Arora S, Wladyka CL, Pushpa Itagi, Corey L, Young D, Stackhouse BL, Kollath L, Wu QV, Corey E, True LD, Ha G, Paddison PJ, Hsieh AC. (2023). Multi-level functional genomics reveals molecular and cellular oncogenicity of patient- based 3’ untranslated region mutations. Cell Reports doi: 10.1016/j.celrep.2023.112840
Blinka S, Mishra R, Hsieh AC. (2023). ELAC2 is a functional prostate cancer risk allele. Trends in Molecular Medicine doi: 10.1016/j.molmed.2023.06.002
Mishra R, Blinka S, Hsieh AC. (2023). Prostate cancer progression relies on the mitotic AGC family protein kinase cintron kinase. Cancer Research doi: 10.1158/0008-5472.CAN-23-2858
Kartha N, Gianopulos JE, Schrank Z, Kynnap BD, Wladyka CL, Santana JF, Cavender SM, Bridgewater CM, Fuchs K, Dysinger S, Lampano AE, Price DH, Hsieh AC, Hingorani SR, Kugel S. (2023). SIRT6 is required for the integrated stress response and resistance to transcriptional inhibition. Science Translational Medicine doi: 10.1126/scitranslmed.abn9674
Sekar RR, Diamantopoulos LN, Khaki AR, Grivas P, Winters BR, Vakar-Lopez F, Tretiakova MS, Psutka SP, Holt SK, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Wright JL. (2023). "Sarcomatoid urothelial carcinoma is associated with limited response to neoadjuvant chemotherapy and poor oncologic outcomes after radical cystectomy." Clinical Genitourinary Cancer doi: 10.1016/j.clgc.2023.03.015
Cheng HH, Sokolova AO, Gulati R, Bowen D, Grivas P, Hsieh AC, Klemfuss N, Knerr S, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery RB. (2023). "Internet-based germline genetic testing for men with metastatic prostate cancer." JCO Precision Oncology doi: 10.1200/PO.22.00104
Ghali F, Vakar-Lopez F, Roudier MP, Garcia J, Wang Y, Arora S, Grivas P, Lee JK, Yu EY, Montgomery RB, Hsieh AC, Wright JL, Lam H. (2023). "Metastatic bladder cancer expression and subcellular localization of Nectin-4 and Trop-2 in variant histology: a rapid autopsy study." Clinical Genitourinary Cancer doi: 10.1016/j.clgc.2023.05.014
Hamm DC, Paatela E, Wong C, Bennett SR, Campbell AE, Wladyka CL, Smith AA, Jagannathan S, Hsieh AC, Tapscott SJ. (2023). "DUX4 orchestrates translatome reprogramming by suppressing translation efficiency." PLoS Biology doi: 10.1371/journal.pbio.3002317
Germanos AA, Arora S, Zheng Y, Goddard E, Coleman I, Ku A, Wilkinson S, Song H, Brady NJ, Amezquita RA, Zager M, Long A, Yang C, Bielas J, Gottardo R, Rickman DS, Huang FW, Ghajar CM, Nelson PS, Sowalsky A, Setty M, Hsieh AC. (2022). "Defining cellular population dynamics at single cell resolution during prostate cancer progression." eLIFE doi: 10.7554/eLife.79076
*** For this manuscript, the Hsieh Lab developed an intuitive and searchable website for the scRNAseq analysis which can be found here.
Talukder F, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather_Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Maria GCA, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgin J, Frobe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Hsieh AC, Grivas P, Khaki AR. (2022). "Association of the time to immune checkpoint inhibitor (ICI) initiation and outcomes with second line ICI in patients with advanced urothelial carcinoma." Clinical Genitourinary Cancer doi: 10.1016/j.clgc.2022.08.006
Sonpavde G, Maughan BL, McGregor BA, Wei XX, Kilbridge KL, Lee RJ, Yu EY, Schweizer MT, Montgomery RB, Cheng HH, Hsieh AC, Jain R, Grewal JS, Pico-Navarro C, Gafoor Z, Perschy T, Grivas P. (2022). "Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma." Cancer Immunology, Immunotherapy doi: 10.1007/s00262-022-03274-6
Kim YS, Hsieh AC*, Lam HM*. (2022). "Bladder cancer patient derived organoids and avatars for personalized cancer discovery." European Urology Focus doi: 10.1016/j.euf.2022.07.006
*co-corresponding author.
Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner HC, De Sarkar N, Ha G, Dumpit, R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh AC, Montgomery RB, Nelson PS, Yu EY. (2022). "Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant
prostate cancer." Prostate Cancer Prostatic Dis. doi: 10.1038/s41391-022-00636-0
2021
Lim Y, Arora S, Schuster SL, Corey L, Fitzgibbon M, Wladyka CL, Wu X, Coleman IM, Delrow JJ, Corey E, True LD, Nelson PS, Ha G, Hsieh AC. (2021). "Multiplex functional genomic analysis of 5’ untranslated region mutations across the spectrum of prostate cancer." Nature Communications doi: 10.1038/s41467-021-24445-6
Jana S, Deo R, Hough R, Liu Y, Horn JL, Wright JL, Lam H, Webster K, Chiang GC, Sonenberg N, Hsieh AC. (2021). "mRNA translation is a therapeutic vulnerability necessary for efficient bladder epithelial transformation." JCI Insight doi: 10.1172/jci.insight.144920
Cai EY, Garcia J, Liu Y, Vakar-Lopez F, Arora S, Nguyen H, Brown L, Montgomery RB, Lee JK, Corey E, Wright JL#, Hsieh AC#, Lam H#. (2021). "Bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture." Scientific Reports doi: 10.1038/s41598-021-83662-7 #co-corresponding author.
Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen H, de Stanchina E, Sawyers CL, Rosen N, Hsieh AC, Chen Y, Carver BS. (2021). "Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers." Nature Communications doi: 10.1038/s41467-021-25341-9
Jobava R, Mao Y, Guan B, Hu D, Krokowski D, Chen C, Shu E, Chukwurah E, Wu J Gao Z, Zagore LL, Merrick WC, Trifunovic A, Hsieh AC, Valakhan S, Zhang Y, Qi X, Jankowsky E, Topisirovic I, Licatalosi DD, Qian S, Hatzoglou M. (2021). "Adaptive translational pausing is a hallmark of the cellular response to severe environmental stress." Molecular Cell doi: 10.1016/j.molcel.2021.09.029
Che M, Chaturvedi A, Munro SA, Pitzen S, Ling A, Zhang W, Mentzer J, Ku S, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, Daniel M, Wang T, Selth L, Hickey T, Zoubeidi A, Gleave M, Bareja R, Sboner A, Tilley W, Carroll JS, Tan W, Kohli M, Yang R, Hsieh AC, Murugan P, Zwart W, Beltran H, Huang SR, Dehm SM. (2021). "Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer." Nature Communications doi: 10.1038/s41467-021-26612-1
Diamantopoulos LN, Sekar RR, Holt SK, Khaki AR, Miller NJ, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. (2021). "Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy." Urologic Oncology doi: 10.1016/j.urolonc.2021.01.009
2020
Cai EY, Kufeld MN, Schuster SL, Arora S, Larkin M, Germanos AA, Hsieh AC, Beronja S. (2020). "Selective translation of cell fate regulators mediates tolerance to broad oncogenic stress." Cell Stem Cell doi: 10.1016/j.stem.2020.05.007
Itani OA, Zhong X, Tang X, Scott BA, Yan JY, Flibotte S, Lim Y, Hsieh AC, Bruce JE, Van Gilst M, Crowder M. (2020). “Coordinate regulation of ribosome and tRNA biogenesis controls hypoxic injury and translation.” Current Biology doi: 10.1016/j.cub.2020.10.001
Diamantopoulos LN, Khaki AR, Grivas P, Gore JL, Schade GR, Hsieh AC, Lee JK, Yezefski T, Yu EY, Schweizer MT, Cheng HH, Psutka SP, Lin DW, Tretiakova MS, Vakar-Lopez F, Montgomery RB, Wright JW. (2020). "Plasmacytoid bladder cancer variant: response to chemotherapy and oncologic outcomes." Bladder Cancer doi: 10.3233/BLC-190258
Diamantopoulos LN, Holt SK, Khaki AR, Sekar RR, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. (2020). "Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and Surveillance, Epidemiology, and End Results (SEER) program." Clinical Genitourinary Cancer doi: 10.1016/j.clgc.2020.10.002
2019
Liu Y*, Horn JL*, Banda K*, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. (2019). "Androgen receptor regulates a druggable translational regulon in advanced prostate cancer." Science Translational Medicine doi: 10.1126/scitranslmed.aaw4993 *co-first authors
Kuppers DA, Arora S, Lim Y, Lim A, Carter L, Corrin P, Plasier CL, Basom R, Delrow J, Wang S, He HH, Torok-Storb B, Hsieh AC*, Paddison PJ*. (2019). "N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis." Nature Communications doi: 10.1038/s41467-019-12518-6 *co-corresponding author
Schuster SL, Hsieh AC. (2019). "The untranslated regions of mRNAs in cancer." Trends in Cancer doi: 10.1016/j.trecan.2019.02.011
Winters BR*, De Sakar N*, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas, P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL#, Lam H#, Hsieh AC#. (2019). "Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy." JCI Insight doi: 10.1172/jci.insight.128728 *co-first authors #co-corresponding author
Labrecque, MP, Coleman IM, Brown LG, True LD, Kollath J, Lakely B, Nguyen HM, Yang YC, Kaipainen AH, Coleman RT, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery RB, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. (2019). "Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer." JCI doi: 10.1172/JCI128212
Schweizer M, Antonarakis E, Bismar T, Guedes L, Cheng HH, Tretiakova M, Vakar-Lopez F, Klemfuss N, Konnick E, Mostaghel E, Hsieh AC, Nelson PS, Yu E, Montgomery B, True L, Epstein J, Lotan T, Pritchard C. (2019). "Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations." JCO Precision Oncology doi: 10.1200/PO.18.00327
Diamantopoulos LN, Winters BR, Grivas P, Ngo SD, Zeng J, Hsieh AC, Gore JL, Liao JJ, Yu EY, Schade GR, Psutka SP, Schweizer MT, Lee JH, Dighe M, Lin DW, Cheng HH, Daya J, Tretiakova MS, True LD, Russell KJ, Vakar-Lopez F, Montgomery RB, Wright JL. (2019). "Bladder Cancer Multidisciplinary Clinic (BCMC) model influences disease assessment and impacts treatment recommendations." Bladder Cancer doi: 10.3233/BLC-190239
2018
Graham L, Banda K, Pisano, K, Shelley G, Curley T, Scher HI, Lotan TL, Hsieh AC*, Rathkopf DE*. (2018). "A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with metastatic castration-resistant prostate cancer." (2018). Investigational New Drugs doi: 10.1007/s10637-018-0578-9 *co-corresponding author
Guzzi N, Ciesla M, Ngoc P, Lang S, Arora S, Dimitrious M, Pimkova K, Sommarin MNE, Munita R, Lubas M, Lim Y, Okuyama K, Soneji S, Karlsson G, Hansson J, Jonsson G, Lund AH, Sigvardsson M, Hellstrom-Lindberg E, Hsieh AC, Bellodi C. (2018). "Pseudouridylation of tRNA-derived fragments steers translational control in stem cells." Cell doi: 10.1016/j.cell.2018.03.008
Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang J, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. (2018). "Development of a stress response therapy targeting aggressive prostate cancer." Science Translational Medicine doi: 10.1126/scitranslmed.aar2036
Winters BR, Vakar-Lopez F, Brown L, Montgomery RB, Seiler R, Black P, Boormans JL, Dall'Era M, Davincioni E, Douglas J, Gibb E, Van Rhijn BWG, Van der Heijden M, Hsieh AC, Wright JL, Lam H. (2018). "Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy." Urologic Oncology doi: 10.1016/j.urolonc.2018.03.016
2017
Bluemn, EG, Coleman I, Lucas JM, Coleman R, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit R, Kaipainen A, Corella A, Yang YC, Nyquist M, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown L, Nguyen H, Pienta K, Ittman M, Schweizer M, True L, Wise D, Rennie PS, Vessella R, Morrissey C, Nelson PS. (2017). "Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling." Cancer Cell doi: 10.1016/j.ccell.2017.09.003
Jana S, Hsieh AC, Gupta R. (2017). "Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis." Cell Death & Disease doi: 10.1038/cddis.2017.476
Wei XX, Hsieh AC, Kim W, Friedlander TW, Lin AM, Louttit M, Ryan CJ. (2017). "A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer." The Oncologist doi: 10.1634/theoncologist.2016-0432
2015
Hsieh AC*, Nguyen HG, Wen L, Edlind MP, Carroll P, Kim W, Ruggero D.* (2015). "Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors." Science Signaling doi: 10.1126/scisignal.aad5111 *co-corresponding author
Sheridan CM, Grogan T, Nguyen HG, Rettig M*, Hsieh AC*, Ruggero D.* (2015). "YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence."Oncotarget doi: 10.18632/oncotarget.3477 *co-corresponding author
Publications prior to joining Fred Hutch
2014
Edlind MP, Hsieh AC. (2014). "PI3K-AKT-mTOR signalling in prostate cancer progression and androgen deprivation therapy resistance." Asian Journal of Andrology doi: 10.4103/1008-682X.122876
Long-Cheng L, Hsieh AC, Ruggero D, Greene KL, Carroll PR. (2014). Molecular basis of prostate cancer. In: "The Molecular Basis of Cancer, 4th Edition." Mendelsohn J, Howley P, Israel M, Gray J, Thompson C. (eds). doi: 10.1016/B978-1-4557-4066-6.00038-X
2013
Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, Taylor BS. (2013). "Assessing gene-level translational control from ribosome profiling." Bioinformatics doi: 10.1093/bioinformatics/btt533
2012
Hsieh AC*, Liu Y*, Edlind MP, Ingolia, NT, Janes MR, Sher A, Shi EY, Christensen C, Stumpf CR, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. (2012)."The translational landscape of mTOR signaling steers cancer initiation and metastasis." Nature doi: 10.1038/nature10912 *co-first author
2011
Hsieh AC, Truitt ML, Ruggero D. (2011). "Oncogenic AKTivation of translation as a therapeutic target." British Journal of Cancer doi: 10.1038/bjc.2011.241
Kondrashov N, Pusic A, Stumpf, CR, Shimizu K, Hsieh AC, Ishijima J, Kikkawa Y, Shiroishi T, Barna M. (2011). "Ribosome-mediated specificity of Hox mRNA translation and vertebrate tissue patterning." Cell doi: 10.1016/j.cell.2011.03.028
2010
Hsieh AC*, Costa M*, Zollo O, Davis C, Feldman M, Testa JR, Meyuhas O, Shokat K, Ruggero D. (2010). "Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E." Cancer Cell doi: 10.1016/j.ccr.2010.01.021 *co-first author
Hsieh AC, Ruggero D. (2010). "Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer." Clinical Cancer Research doi: 10.1158/1078-0432.CCR-10-0433
2009
Mawad R, Hsieh AC, Damon L. (2009). "Graft-versus-Host Disease presenting with pancytopenia after en-bloc multi-organ transplant: case report and literature review." Transplantation Proceedings doi: 10.1016/j.transproceed.2009.06.229
2008
Hsieh AC, Ryan CJ. (2008). "Novel concepts in androgen receptor blockade." Cancer Journal doi: 10.1097/PPO.0b013e318161d13e
2007
Hsieh AC, Moasser MM. (2007). "Targeting HER proteins in cancer therapy and the role of the non-target HER3." British Journal of Cancer doi: 10.1038/sj.bjc.6603910
Hsieh AC*, Small EJ, Ryan CJ. (2007). "Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development." Lancet Oncology doi: 10/1016/S1470-2045(07)70316-9 *corresponding author
2004
Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S, Sellers WR. (2004). "A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens." Nucleic Acid Research doi: 10/1093/nar/gkh238
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.